Looked good here...
Screening and randomisation of patients in ATL1102 Phase IIb trial is progressing well with five
boys having received their first dose of ATL1102 or Placebo as of 24 July 2023 and an additional
five boys in screening in Turkey. Site activation in the other countries is ongoing with a further site
scheduled to open imminently, four sites with activation activities confirmed for August and one
for September. The Antisense clinical operations team and Parexel are working closely with
remaining sites to expedite contract completion with more activation activities scheduled as
contracts are finalised. Investigators and their DMD patient families remain excited about
participation in the study and are eagerly awaiting commencement of their involvement in the
study.
That's 10 in Turkey if all went well .
5 more sites active by now would see some decent numbers on board..
Fingers crossed
ANP Price at posting:
6.3¢ Sentiment: Buy Disclosure: Held
